Discussion on the optimization of personalized medication using information systems based on pharmacogenomics: an example using colorectal cancer
Frontiers in Pharmacology,
Journal Year:
2025,
Volume and Issue:
15
Published: Jan. 14, 2025
Pharmacogenomics
(PGx)
is
a
powerful
tool
for
clinical
optimization
of
drug
efficacy
and
safety.
However,
due
to
many
factors
affecting
drugs
in
the
real
world,
PGx
still
accounts
small
proportion
actual
application
scenarios.
Therefore,
based
on
information
software,
pharmacists
use
their
professional
advantages
integrate
into
all
aspects
pharmaceutical
care,
which
conducive
promoting
development
personalized
medicine.
In
this
paper,
establishment
an
software
platform
summarized
medication
program
PGx.
Taking
colorectal
cancers
(CRC)
as
example,
paper
also
discusses
role
different
working
modes
participation
management
CRC
patients
by
with
help
systems.
Finally,
we
recommendations
guidelines
provide
reference
follow-up
care.
Language: Английский
Enhancing Rural Healthcare Accessibility: A Model for Pharmacogenomics Adoption via an Outreach-Focused Integration Strategy
Jared Silver,
No information about this author
Evan M. Forman,
No information about this author
David Barrett
No information about this author
et al.
Journal of Personalized Medicine,
Journal Year:
2025,
Volume and Issue:
15(3), P. 110 - 110
Published: March 13, 2025
Background/Objectives:
Pharmacogenomics
is
an
emerging
field
in
precision
medicine
that
aims
to
improve
patient
outcomes
by
tailoring
drug
selection
and
dosage
individual’s
genetic
makeup.
However,
patients
rural
communities
often
cannot
take
advantage
of
specialized
services
such
as
pharmacogenomics
due
various
barriers
limit
access
healthcare.
This
article
identify
the
implementing
pharmacogenomic
initiatives
assess
strategies
for
integrating
into
healthcare
systems.
Methods:
describes
qualitative
research
was
conducted
using
semi-structured
interviews
with
stakeholders
addition
explaining
how
strategic
frameworks
were
used
synthesize
secondary
research.
Results:
The
findings
this
indicated
mixed
awareness
option
amongst
stakeholders,
highlighting
need
targeted
outreach
education
intervention.
Solutions
mail-in
testing
telemedicine
determined
be
feasible
solutions
address
geographical
logistical
exist
patients.
determines
successful
will
leverage
existing
infrastructure
prioritize
care,
workflow
integration,
adoption.
Conclusions:
Making
a
viable
multi-faceted
approach
combines
outreach,
education,
innovative
delivery
models
overcome
multiple
facing
communities.
Language: Английский
Exploring the Clinical Workflow in Pharmacogenomics Clinics: An Observational Study
Journal of Personalized Medicine,
Journal Year:
2025,
Volume and Issue:
15(4), P. 146 - 146
Published: April 5, 2025
Background:
Pharmacogenomics
(PGx)
is
the
future
of
healthcare
and
implementation
being
driven
by
increasing
evidence.
Understanding
workflow
in
a
PGx
clinic
provides
insight
into
development
services.
It
considers
patient’s
perspective,
role
interprofessional
team
pivotal
input
pharmacist.
Objectives:
The
purpose
this
study
was
to
describe
clinical
followed
selected
clinics.
Methods:
Four
different
sites
that
offer
services
(United
States
America)
were
included.
Qualitative
data
collected
through
semi-structured
interviews
observations
providing
valuable
insights
both
community-based
hospital-based
Results:
Although
each
setting
differed,
processes
similar
with
setting-specific
workflows
barriers.
This
highlights
pharmacist
team,
resources
used
for
interpretation
test
results
importance
patient
education.
Conclusions:
essential
ensure
successful
sustainable
precision
medicine
practices
resource-limited
settings.
Language: Английский
Integrating pharmacogenomics in three Middle Eastern countries’ healthcare (Lebanon, Qatar, and Saudi Arabia): Current insights, challenges, and strategic directions
PLoS ONE,
Journal Year:
2025,
Volume and Issue:
20(4), P. e0319042 - e0319042
Published: April 11, 2025
Background
and
objectives
Pharmacogenomics
(PGx)
leverages
genomic
information
to
tailor
drug
therapies,
enhancing
precision
medicine.
Despite
global
advancements,
its
implementation
in
Lebanon,
Qatar,
Saudi
Arabia
faces
unique
challenges
clinical
integration.
This
study
aimed
investigate
PGx
attitudes,
knowledge
implementation,
associated
challenges,
forecast
future
educational
needs,
compare
findings
across
the
three
countries.
Methods
cross-sectional
utilized
an
anonymous,
self-administered
online
survey
distributed
healthcare
professionals,
academics,
clinicians
Arabia.
The
comprised
18
questions
assess
participants’
familiarity
with
PGx,
current
practices,
perceived
obstacles,
potential
integration
strategies,
needs.
Results
yielded
337
responses
from
professionals
Data
revealed
significant
variations
involvement.
Qatar
participants
were
more
familiar
compared
Lebanon
(83%,
75%,
67%,
respectively).
Participation
PGx-related
talks
was
most
prevalent
(96%),
followed
by
(53%)
(35%).
Key
identified
included
test
cost
reimbursement,
insufficient
physician
knowledge,
lack
of
infrastructure.
reported
highest
concern
for
costs
(16%),
lowest
(5%).
these
a
strong
consensus
emerged
on
PGx’s
improve
patient
outcomes,
over
86%
respondents
all
countries
expressing
this
belief.
Educational
interest
areas
varied
country,
cancer
chemotherapy
diabetes
mellitus
Qatar.
Conclusion
highlights
influence
backgrounds
infrastructural
limitations
emphasize
need
targeted
strategies
each
country
address
distinct
barriers.
Integrating
education
into
training
programs
workflows
could
unlock
optimize
care.
Language: Английский
The Potential Roles of Pharmacists in the Clinical Implementation of Pharmacogenomics
Abdullah Al Maruf,
No information about this author
Md. Abdul Aziz
No information about this author
Pharmacy,
Journal Year:
2023,
Volume and Issue:
11(6), P. 180 - 180
Published: Nov. 19, 2023
The
field
of
pharmacogenomics
is
at
the
forefront
a
healthcare
revolution,
promising
to
usher
in
new
era
precision
medicine
[...].
Language: Английский
Knowledge and perceptions of pharmacogenomics among pharmacists in Manitoba, Canada
Abdullah Al Maruf,
No information about this author
Meagan Shields,
No information about this author
Amber Fryza
No information about this author
et al.
Pharmacogenomics,
Journal Year:
2024,
Volume and Issue:
25(4), P. 175 - 186
Published: March 1, 2024
Objective:
This
work
was
designed
to
describe
the
knowledge
and
perceptions
of
pharmacogenomics
(PGx)
among
pharmacists
in
Canadian
province
Manitoba.
Methods:
A
40-item,
web-based
survey
distributed
Results:
Of
74
participants,
one
third
had
some
education
or
training
PGx,
12.2%
used
PGx
test
results
their
practice.
Participants'
self-rated
testing
common
resources
(e.g.,
Pharmacogenomics
Knowledge
Base,
Clinical
Pharmacogenetics
Implementation
Consortium)
low.
Most
surveyed
believe
that
can
improve
medication
efficacy
(82.4%)
prevent
adverse
drug
reactions
(81.1%).
(91%)
desired
more
on
PGx.
Conclusion:
Manitoba
reported
positive
toward
However,
they
are
currently
underprepared
implement
into
Language: Английский
Here is my sequence: The pharmacist's role in interpreting pharmacogenomic results
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY,
Journal Year:
2024,
Volume and Issue:
7(3), P. 194 - 195
Published: March 1, 2024
The
author
declares
no
conflicts
of
interest.
Dr.
Caudle
is
a
member
the
JACCP
editorial
board.
Language: Английский
Farmakogenetsko profiliranje pedijatrijskih onkoloških bolesnika: iskustvo jednog centra
Paediatria Croatica,
Journal Year:
2024,
Volume and Issue:
68(2), P. 55 - 64
Published: July 23, 2024
Aim:
As
the
results
of
pharmacogenetic
studies
are
increasingly
translated
into
clinical
practice,
ultimate
goal
personalising
treatment
for
children
with
cancer
seems
achievable
in
future.
Our
survey
aimed
to
establish
what
extent
pharmacogenetics
has
already
been
utilised
everyday
work.Methods:
A
retrospective
on
testing
treated
malignancies
at
Department
Oncology
and
Haematology,
Children’s
Hospital
Zagreb,
from
2021
2023
was
carried
out.Results:
Pharmacogenetic
performed
17.2%
180
(53.3%
female,
median
age
7.0
years),
greatest
number
tests
obtained
2023.
Preemptive
included
thiopurine
S-methyltransferase
polymorphisms
(in
94.4%
acute
lymphoblastic
leukaemia
33.3%
eosinophilic
granuloma)
methylenetetrahydrofolate
reductase
gene
poly-morphisms
assaying
55.6%
23.1%
osteosarcoma
patients).
In
8
children,
made
due
adverse
events
(25%
lung
75%
liver
injury,
all
grade
4),
majority
cases
presumably
related
vincristine.
were
pathological
reactively
tested
patients,
requiring
dose
modification/chemotherapeutics
omission
87.5%
cases.Conclusion:
The
assays
high-grade
continuously
rising,
steering
otherwise
standardised
towards
a
more
individualised
approach.
Methyltransferase
Polymorphism
routinely
done
almost
patients
planned
receive
thiopurines.
However,
research
is
needed
drug-gene
pairs
field
paediatric
oncology
minimise
treatment-related
toxicity
optimise
outcomes.
Language: Английский
Understanding general practitioner and pharmacist preferences for pharmacogenetic testing in primary care: a discrete choice experiment
The Pharmacogenomics Journal,
Journal Year:
2024,
Volume and Issue:
24(5)
Published: Aug. 9, 2024
Pharmacogenetic
testing
in
the
United
Kingdom's
National
Health
Service
(NHS)
has
historically
been
reactive
nature,
undertaken
context
of
single
gene-drug
relationships
specialist
settings.
Using
a
discrete
choice
experiment
we
aimed
to
identify
healthcare
professional
preferences
for
development
pharmacogenetic
service
primary
care
NHS.
Respondents,
representing
two
professions
groups
(general
practitioners
or
pharmacists),
completed
one
survey
versions,
asking
them
select
their
preferred
presentation
low
mood
joint
pain.
Responses
from
235
individuals
were
included.
All
respondents
over
no
testing,
though
preference
heterogeneity
was
identified.
Both
groups,
but
especially
GPs,
highly
sensitive
design,
with
uptake
varying
depending
on
offered.
This
study
demonstrates
is
impacted
by
design
and
highlights
key
areas
which
should
be
prioritised
within
future
initiatives.
Language: Английский